Concepedia
Statistics
Publications
24
Citations
1K
H-Index
18
Active since
1980
Affiliations
Pfizer (United States)(Current)
Repligen (United States)
Pfizer (United Kingdom)
MSD (UK) Limited (United Kingdom)
Bertrand L. Chenard is an author at Pfizer (United States) specializing in pharmacology, medicinal chemistry, and medicine.
Publications per year
1980–2018
Treatment with HC-070, a potent inhibitor of TRPC4 and TRPC5, leads to anxiolytic and antidepressant effects in mice
Stefan Just, Bertrand L. Chenard, Angelo Ceci et al. · PLoS ONE · 2018 · 139 citations · Full text
Medicine, Neuroscience, Pharmacology +17
CP-101,606, a potent neuroprotectant selective for forebrain neurons
Frank S. Menniti, Bertrand L. Chenard, Mary Collins et al. · European Journal of Pharmacology · 1997 · 111 citations
Life Sciences, Neuroscience, Pharmacology +12
.alpha.-Nitroarylation of ketones and esters: an exceptionally facile synthesis of indoles, 2-indolinones and arylacetic acids
T. V. RajanBabu, Bertrand L. Chenard, Michael A. Petti · The Journal of Organic Chemistry · 1986 · 85 citations
Natural Sciences, Chemistry, Medicinal Chemistry +9
Transient receptor potential ion channels as targets for the discovery of pain therapeutics.
James E. Krause, Bertrand L. Chenard, Daniel N. Cortright · PubMed · 2005 · 59 citations
Life Sciences, Pharmacology, Inflammation +16
CP-101,606, an NR2B subunit selective NMDA receptor antagonist, inhibits NMDA and injury induced c-fos expression and cortical spreading depression in rodents
Frank S. Menniti, Martin J. Pagnozzi, Paul Butler et al. · Neuropharmacology · 2000 · 56 citations
Life Sciences, Neuroscience, Pharmacology +11
1–5 of 24